Navigation Links
ACell's CEO to Present at Rodman & Renshaw's 2009 Annual Global Investment Conference
Date:9/2/2009

COLUMBIA, Md., Sept. 2 /PRNewswire/ -- ACell, Inc. is announcing its participation at Rodman & Renshaw's 2009 Annual Global Investment Conference.

The conference will be held September 9, 2009 through September 11, 2009 at the New York Palace Hotel in New York City. James DeFrancesco, Chief Executive Officer and President, is scheduled to make an investor presentation on September 11th beginning at 9:10 AM (EDT) in the Hubbard Room. The presentation is expected to take approximately 25 minutes. Investors and strategic partners interested in ACell's proprietary technology are encouraged to contact the company for private one on one discussion while attending the conference.

Mr. DeFrancesco's presentation will provide an update on ACell's regenerative medicine technology and share clinical results of recently completed cases. ACell introduced its wound care devices utilizing a major marketing partner last January. Now, with the recent release of several new extracellular matrix (ECM) surgical devices, ACell is targeting the US plastic surgery, hernia and trauma markets. Several orthopedic products are scheduled for release next year. The company has recently received significant media coverage for the involvement of its MatriStem((R)) MicroMatrix(TM) in re-growing severed fingertips.

ACell Inc.

ACell is a private company with multiple US and international patents for its proprietary UBM (Urinary Bladder Matrix) ECM technology. ACell's advanced bio-scaffold devices consist of an intact epithelial basement membrane, naturally derived bioactive molecules and multiple collagen types known to assist the body in the regeneration of new tissues. Commercially branded as MatriStem((R)), UBM can be used in a broad range of regenerative medicine applications. ACell currently has five FDA 510(k) clearances addressing wound care and various surgical indications.

www.acell.com


'/>"/>
SOURCE ACell, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Transcept Pharmaceuticals to Present at the BioCentury Thomson Reuters Newsmakers in the Biotech Industry Conference on September 16, 2009
2. BioMarin to Present at the Baird Healthcare Conference
3. Poniard Pharmaceuticals To Present at Three Upcoming Investor Conferences in September
4. NeurogesX to Present at Upcoming Fall Conferences
5. Repligen to Present at the Rodman & Renshaw 11th Annual Healthcare Conference Wednesday, September 9th, 2:25 p.m. EDT
6. Optimer Pharmaceuticals Announces Presentations of Additional Phase 3 Fidaxomicin and Prulifloxacin Data at Upcoming ICAAC Annual Meeting
7. Jiangbo Pharmaceuticals to Present at Rodman & Renshaw Annual Global Investment Conference
8. Express Scripts to Present at Investor Conferences
9. ERT to Present at Bairds 2009 Health Care Conference on September 9, 2009
10. PharmAthene to Present at the Rodman and Renshaw Annual Global Investment Conference September 10, 2009
11. PAREXEL International to Present at Robert Baird 2009 Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... On Thursday, March 23, 2017, ... down 0.07%; the Dow Jones Industrial Average edged 0.02% ... closed at 2,345.96, marginally dropping 0.11%. US markets saw ... 4 sectors finished in red, and 1 sector ended ... reports coverage on the following Biotechnology equities: BioDelivery Sciences ...
(Date:3/23/2017)... (PRWEB) , ... March 23, 2017 , ... ... viscoelastic material that exhibits both viscous and elastic characteristics when deformed, which is ... polymer exhibits properties to gently absorb compressive forces and return to its natural ...
(Date:3/23/2017)... March 23, 2017  Northwest Biotherapeutics (OTCQB: NWBO) ... immune therapies for solid tumor cancers, today announced ... financing it announced last Friday, March 17, 2017. ... institutional investors securities totaling 28,843,692 shares, comprised of ... 10,000,000 shares of Class C Warrants pre-funded at ...
(Date:3/23/2017)... MENLO PARK, Calif., March 23, 2017  BioPharmX ... developing products for the dermatology market, today reported ... Jan. 31, 2017, and will provide an update ... from the year. "We are pleased ... productive year for BioPharmX," said President Anja Krammer. ...
Breaking Biology Technology:
(Date:2/27/2017)... 2017   Strategic Cyber Ventures , the industry,s ... a $3.5 million investment in  Polarity , the first ... is DC based and is led by cybersecurity veterans ... Ron Gula , also a longtime cybersecurity veteran ... this series A round of funding. This new funding ...
(Date:2/21/2017)... , February 21, 2017 ... 70 Millionen US-Dollar wachsen. Nach einem Gespräch mit mehr als ... einige Hindernisse zu überwinden gilt, um diese Prognose zu ... ... anderem die Mobilisierung der finanziellen Mittel für die Biobank, ...
(Date:2/10/2017)... 2017 Research and Markets has ... Medicine - Scientific and Commercial Aspects" to their offering. ... ... integrated with therapy for selection of treatment as well for ... prevention of disease in modern medicine. Biochip/microarray technologies and next ...
Breaking Biology News(10 mins):